Isomorphic Labs secures a $2.1B Series B to scale AI-driven drug discovery, while the FDA launches causal AI pilots aiming to cut clinical trial timelines by up to 40%.
Isomorphic Labs, the AI drug discovery company founded by DeepMind's Demis Hassabis, has raised $2.1 billion in Series B funding led by Thrive Capital. The round includes Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
The FDA has launched a first-of-its-kind pilot using cloud-based causal AI to shorten drug and medical device clinical trial timelines by 20–40%. FDA Chief AI Officer Jeremy Walsh says the approach could also accelerate regulatory approval timelines.